Browsing Tag
biotech licensing
3 posts
OSR Holdings (NASDAQ: OSRH) explores royalty-driven licensing for Vaximm’s cancer therapy
Vaximm may license its oral cancer therapy VXM01 in a deal worth up to $815M. Find out how OSR Holdings plans to turn this into a royalty-driven biotech play.
Vaximm AG advances VXM01 strategy with BCM Europe term sheet offering US$20m upfront and US$815m upside
Learn how Vaximm AG’s new term sheet with BCM Europe sets the stage for a US$20M upfront license deal and up to US$815M in milestones.
Will Biogen’s $1bn bet on Vanqua Bio’s oral inflammation drug jumpstart its post-MS future?
Biogen’s $1.06B Vanqua Bio licensing deal signals a strategic shift toward immunology. Explore the roadmap behind this bold preclinical move.